 Suchitra Rao
Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 23 | 2024 | 548 | 8.610 |
Why?
| | Influenza Vaccines | 13 | 2024 | 498 | 3.830 |
Why?
| | Respiratory Tract Infections | 5 | 2023 | 323 | 2.520 |
Why?
| | Respiratory Syncytial Virus, Human | 3 | 2023 | 60 | 2.430 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2023 | 97 | 2.350 |
Why?
| | Vaccination | 15 | 2024 | 1210 | 2.300 |
Why?
| | Hospitalization | 23 | 2024 | 1765 | 1.640 |
Why?
| | Influenza A Virus, H1N1 Subtype | 4 | 2023 | 139 | 1.620 |
Why?
| | Child | 39 | 2024 | 18503 | 1.190 |
Why?
| | Coinfection | 2 | 2022 | 120 | 1.110 |
Why?
| | Connective Tissue Diseases | 2 | 2023 | 71 | 1.060 |
Why?
| | Child, Preschool | 24 | 2023 | 9138 | 1.050 |
Why?
| | Infant | 19 | 2023 | 7979 | 1.040 |
Why?
| | Polyomavirus Infections | 3 | 2016 | 22 | 1.000 |
Why?
| | Influenza A Virus, H3N2 Subtype | 4 | 2024 | 40 | 0.990 |
Why?
| | Polyomavirus | 3 | 2016 | 9 | 0.950 |
Why?
| | Immunocompromised Host | 3 | 2021 | 197 | 0.940 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2023 | 71 | 0.920 |
Why?
| | Colorado | 12 | 2023 | 4116 | 0.920 |
Why?
| | Retrospective Studies | 20 | 2024 | 12633 | 0.910 |
Why?
| | Ageusia | 1 | 2022 | 1 | 0.860 |
Why?
| | Metapneumovirus | 1 | 2022 | 12 | 0.830 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2021 | 147 | 0.810 |
Why?
| | Humans | 74 | 2024 | 115741 | 0.800 |
Why?
| | Myocarditis | 1 | 2022 | 94 | 0.760 |
Why?
| | Viruses | 1 | 2022 | 94 | 0.760 |
Why?
| | Antiviral Agents | 4 | 2024 | 649 | 0.760 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 91 | 0.710 |
Why?
| | Endpoint Determination | 1 | 2020 | 69 | 0.710 |
Why?
| | Seizures | 2 | 2020 | 344 | 0.680 |
Why?
| | Advisory Committees | 1 | 2020 | 208 | 0.660 |
Why?
| | Respiratory Tract Diseases | 2 | 2021 | 142 | 0.660 |
Why?
| | Streptococcal Infections | 1 | 2021 | 132 | 0.650 |
Why?
| | Birth Order | 1 | 2019 | 12 | 0.650 |
Why?
| | Sinusitis | 1 | 2021 | 175 | 0.640 |
Why?
| | Onchocerciasis | 2 | 2015 | 7 | 0.640 |
Why?
| | Encephalitis | 2 | 2017 | 127 | 0.620 |
Why?
| | Viral Load | 4 | 2024 | 405 | 0.580 |
Why?
| | Nervous System Diseases | 1 | 2020 | 253 | 0.560 |
Why?
| | Emergency Service, Hospital | 14 | 2024 | 1829 | 0.560 |
Why?
| | Adolescent | 27 | 2024 | 17922 | 0.550 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 296 | 0.540 |
Why?
| | Medical Audit | 1 | 2016 | 75 | 0.540 |
Why?
| | Oseltamivir | 1 | 2016 | 11 | 0.530 |
Why?
| | Male | 30 | 2024 | 56050 | 0.500 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 72 | 0.500 |
Why?
| | Spinal Cord Diseases | 1 | 2015 | 39 | 0.490 |
Why?
| | Case-Control Studies | 9 | 2023 | 3037 | 0.490 |
Why?
| | Acyclovir | 1 | 2015 | 100 | 0.470 |
Why?
| | Seasons | 5 | 2024 | 449 | 0.470 |
Why?
| | Female | 30 | 2024 | 60018 | 0.470 |
Why?
| | Attitude to Health | 1 | 2017 | 409 | 0.460 |
Why?
| | Enterovirus Infections | 1 | 2016 | 160 | 0.460 |
Why?
| | Ambulatory Care | 6 | 2023 | 479 | 0.460 |
Why?
| | Health Promotion | 1 | 2019 | 693 | 0.440 |
Why?
| | Infection Control | 1 | 2014 | 136 | 0.430 |
Why?
| | Mothers | 1 | 2019 | 666 | 0.430 |
Why?
| | Cohort Studies | 8 | 2023 | 4949 | 0.430 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1537 | 0.420 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 478 | 0.410 |
Why?
| | Cross Infection | 1 | 2014 | 202 | 0.410 |
Why?
| | Health Personnel | 1 | 2017 | 582 | 0.400 |
Why?
| | Virus Diseases | 1 | 2014 | 200 | 0.400 |
Why?
| | Hematologic Diseases | 1 | 2011 | 57 | 0.370 |
Why?
| | Infant, Newborn | 7 | 2023 | 5061 | 0.370 |
Why?
| | Outpatients | 2 | 2024 | 330 | 0.360 |
Why?
| | Parents | 1 | 2017 | 1207 | 0.340 |
Why?
| | Stomach Rupture | 1 | 2009 | 2 | 0.330 |
Why?
| | Liver Abscess, Amebic | 1 | 2009 | 3 | 0.330 |
Why?
| | Pericardial Effusion | 1 | 2009 | 21 | 0.320 |
Why?
| | Pleural Effusion | 1 | 2009 | 47 | 0.320 |
Why?
| | Peritonitis | 1 | 2009 | 76 | 0.310 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 646 | 0.310 |
Why?
| | Adult | 24 | 2024 | 30789 | 0.310 |
Why?
| | Pandemics | 3 | 2023 | 1335 | 0.300 |
Why?
| | Immunization, Secondary | 3 | 2022 | 82 | 0.290 |
Why?
| | Motivation | 2 | 2022 | 498 | 0.280 |
Why?
| | Angiostrongylus cantonensis | 2 | 2018 | 3 | 0.270 |
Why?
| | Strongylida Infections | 2 | 2018 | 6 | 0.270 |
Why?
| | Young Adult | 9 | 2022 | 10518 | 0.260 |
Why?
| | Electronic Health Records | 3 | 2023 | 805 | 0.260 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 125 | 0.240 |
Why?
| | United States | 15 | 2024 | 12304 | 0.230 |
Why?
| | Ritonavir | 1 | 2024 | 72 | 0.220 |
Why?
| | Physicians | 2 | 2023 | 776 | 0.220 |
Why?
| | Severity of Illness Index | 3 | 2022 | 2586 | 0.220 |
Why?
| | Vaccines, Combined | 4 | 2023 | 46 | 0.220 |
Why?
| | Risk Factors | 5 | 2024 | 8702 | 0.210 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2016 | 317 | 0.210 |
Why?
| | Inpatients | 2 | 2017 | 380 | 0.210 |
Why?
| | Propensity Score | 1 | 2024 | 225 | 0.210 |
Why?
| | Child, Hospitalized | 1 | 2023 | 39 | 0.210 |
Why?
| | Vital Signs | 1 | 2022 | 36 | 0.210 |
Why?
| | Viral Vaccines | 1 | 2023 | 90 | 0.200 |
Why?
| | Prospective Studies | 3 | 2024 | 6276 | 0.200 |
Why?
| | Cough | 1 | 2022 | 107 | 0.200 |
Why?
| | Anticonvulsants | 1 | 2023 | 181 | 0.190 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.190 |
Why?
| | RNA, Messenger | 6 | 2023 | 2574 | 0.190 |
Why?
| | Absenteeism | 1 | 2020 | 40 | 0.180 |
Why?
| | Confusion | 1 | 2020 | 25 | 0.170 |
Why?
| | Antibodies, Viral | 2 | 2023 | 527 | 0.170 |
Why?
| | Critical Pathways | 1 | 2020 | 75 | 0.170 |
Why?
| | Encephalitis, Viral | 1 | 2020 | 39 | 0.170 |
Why?
| | Immunization Schedule | 2 | 2021 | 184 | 0.170 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 289 | 0.160 |
Why?
| | Oxygen | 1 | 2023 | 837 | 0.160 |
Why?
| | Brain Diseases | 1 | 2020 | 127 | 0.160 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 119 | 0.160 |
Why?
| | Needs Assessment | 1 | 2020 | 318 | 0.160 |
Why?
| | Information Dissemination | 1 | 2020 | 193 | 0.160 |
Why?
| | Infant, Small for Gestational Age | 1 | 2019 | 76 | 0.150 |
Why?
| | Interprofessional Relations | 1 | 2020 | 258 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 125 | 0.150 |
Why?
| | Communicable Diseases | 1 | 2020 | 130 | 0.150 |
Why?
| | Reminder Systems | 1 | 2019 | 162 | 0.150 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 206 | 0.150 |
Why?
| | Anti-Infective Agents | 1 | 2020 | 225 | 0.150 |
Why?
| | Disease Outbreaks | 2 | 2020 | 308 | 0.150 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 61 | 0.150 |
Why?
| | Cost of Illness | 2 | 2016 | 257 | 0.150 |
Why?
| | Body Mass Index | 2 | 2022 | 1971 | 0.150 |
Why?
| | Neoplasms | 1 | 2011 | 2118 | 0.150 |
Why?
| | Nurses | 1 | 2019 | 151 | 0.150 |
Why?
| | Critical Care | 1 | 2021 | 477 | 0.140 |
Why?
| | Adiposity | 1 | 2022 | 468 | 0.140 |
Why?
| | Fatigue | 1 | 2018 | 296 | 0.140 |
Why?
| | Tertiary Healthcare | 1 | 2016 | 29 | 0.140 |
Why?
| | Philippines | 1 | 2016 | 50 | 0.140 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 58 | 0.140 |
Why?
| | Urban Population | 1 | 2019 | 406 | 0.130 |
Why?
| | Program Evaluation | 1 | 2020 | 836 | 0.130 |
Why?
| | Nasal Cavity | 1 | 2016 | 47 | 0.130 |
Why?
| | Onchocerca | 1 | 2015 | 2 | 0.130 |
Why?
| | Middle Aged | 12 | 2024 | 27069 | 0.130 |
Why?
| | Zoonoses | 1 | 2015 | 21 | 0.130 |
Why?
| | Aged | 9 | 2024 | 19294 | 0.130 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 28 | 0.130 |
Why?
| | Rural Population | 1 | 2019 | 450 | 0.130 |
Why?
| | Dog Diseases | 1 | 2015 | 41 | 0.130 |
Why?
| | Computational Biology | 1 | 2019 | 537 | 0.130 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 20 | 0.120 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 20 | 0.120 |
Why?
| | Electroencephalography | 1 | 2017 | 365 | 0.120 |
Why?
| | Drug Utilization | 1 | 2016 | 167 | 0.120 |
Why?
| | Incidence | 1 | 2021 | 2335 | 0.120 |
Why?
| | Hospitals | 3 | 2024 | 585 | 0.120 |
Why?
| | Pregnancy | 3 | 2022 | 5553 | 0.120 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 106 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 374 | 0.110 |
Why?
| | Aged, 80 and over | 5 | 2022 | 6423 | 0.110 |
Why?
| | Transcriptome | 1 | 2019 | 736 | 0.110 |
Why?
| | Patient Discharge | 1 | 2019 | 770 | 0.110 |
Why?
| | Quality Improvement | 1 | 2020 | 958 | 0.110 |
Why?
| | Survival Rate | 1 | 2017 | 1651 | 0.110 |
Why?
| | Decision Making | 1 | 2018 | 791 | 0.100 |
Why?
| | Meningitis | 1 | 2013 | 74 | 0.100 |
Why?
| | Logistic Models | 1 | 2016 | 1856 | 0.100 |
Why?
| | Critical Illness | 1 | 2016 | 645 | 0.100 |
Why?
| | Registries | 1 | 2019 | 1770 | 0.090 |
Why?
| | Time Factors | 3 | 2022 | 6171 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1218 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 95 | 0.090 |
Why?
| | Eosinophilia | 1 | 2013 | 187 | 0.090 |
Why?
| | Internship and Residency | 1 | 2019 | 951 | 0.090 |
Why?
| | Pediatrics | 1 | 2017 | 986 | 0.090 |
Why?
| | Paromomycin | 1 | 2009 | 2 | 0.080 |
Why?
| | DNA, Viral | 1 | 2011 | 351 | 0.080 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.080 |
Why?
| | Entamoeba histolytica | 1 | 2009 | 7 | 0.080 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 12 | 0.080 |
Why?
| | Metronidazole | 1 | 2009 | 19 | 0.080 |
Why?
| | Hospital Mortality | 2 | 2023 | 779 | 0.080 |
Why?
| | Drainage | 1 | 2009 | 151 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2023 | 9162 | 0.080 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.070 |
Why?
| | Insect Bites and Stings | 1 | 2007 | 13 | 0.070 |
Why?
| | Animals | 6 | 2018 | 32104 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 29 | 0.070 |
Why?
| | Plasmodium falciparum | 1 | 2007 | 27 | 0.070 |
Why?
| | Malaria, Falciparum | 1 | 2007 | 25 | 0.070 |
Why?
| | Viral Proteins | 1 | 2009 | 286 | 0.070 |
Why?
| | Disease Progression | 2 | 2023 | 2423 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 4669 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 519 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3122 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2373 | 0.060 |
Why?
| | Safety | 1 | 2007 | 298 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1357 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 4 | 0.060 |
Why?
| | Genotype | 1 | 2009 | 1787 | 0.060 |
Why?
| | Pneumonia | 1 | 2009 | 576 | 0.060 |
Why?
| | Acetamides | 1 | 2023 | 25 | 0.050 |
Why?
| | Bradycardia | 1 | 2023 | 48 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 12 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 63 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 42 | 0.050 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 144 | 0.050 |
Why?
| | Machine Learning | 1 | 2023 | 321 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2393 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2021 | 622 | 0.040 |
Why?
| | Databases, Factual | 1 | 2022 | 1139 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1086 | 0.040 |
Why?
| | Population Surveillance | 1 | 2020 | 395 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 609 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1473 | 0.030 |
Why?
| | Southwestern United States | 1 | 2015 | 92 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 2839 | 0.030 |
Why?
| | Cats | 1 | 2015 | 204 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2420 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 341 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2911 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4448 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 16 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1500 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1001 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2518 | 0.020 |
Why?
| | Cross Reactions | 1 | 2009 | 117 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 140 | 0.020 |
Why?
| | Age Distribution | 1 | 2009 | 341 | 0.020 |
Why?
| | Parasitemia | 1 | 2007 | 9 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 795 | 0.020 |
Why?
|
|
Rao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|